GSA Capital Partners LLP Trims Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

GSA Capital Partners LLP lowered its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 73.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,494 shares of the biopharmaceutical company’s stock after selling 140,257 shares during the quarter. GSA Capital Partners LLP owned about 0.10% of Puma Biotechnology worth $126,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in PBYI. Rice Hall James & Associates LLC grew its stake in shares of Puma Biotechnology by 3.3% in the 2nd quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 4,686 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Puma Biotechnology by 72.7% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 8,000 shares during the period. SG Americas Securities LLC purchased a new position in Puma Biotechnology in the 1st quarter valued at $57,000. Squarepoint Ops LLC increased its stake in Puma Biotechnology by 17.7% in the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 10,757 shares during the period. Finally, Victory Capital Management Inc. purchased a new position in Puma Biotechnology during the 2nd quarter worth $54,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Analysts Set New Price Targets

PBYI has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Wednesday, November 20th. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday.

Puma Biotechnology Trading Up 0.7 %

NASDAQ:PBYI opened at $3.02 on Tuesday. Puma Biotechnology, Inc. has a 1 year low of $2.22 and a 1 year high of $7.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The stock has a fifty day moving average price of $2.77 and a two-hundred day moving average price of $3.16. The stock has a market capitalization of $148.25 million, a price-to-earnings ratio of 6.29 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same quarter last year, the firm posted $0.12 EPS. As a group, sell-side analysts anticipate that Puma Biotechnology, Inc. will post 0.29 earnings per share for the current fiscal year.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.